# Estuary Biotherapeutics Launches With $103 Million

> Estuary Biotherapeutics secures $103 million to develop gene therapies for kidney disease.
- Title: Estuary Biotherapeutics Launches With $103 Million · Pulse 2.0
- Summary: Estuary Biotherapeutics secures $103 million to develop gene therapies for kidney disease. Estuary Biotherapeutics received $103 million to create gene…
- Keywords: estuary biotherapeutics, adpkd, gene therapy, kidney disease, polycystic kidney disease, pkd1, pkd2, series a, startups, business, Estuary, Biotherapeutics
- Source: Pulse 2.0 — https://pulse2.com/estuary-biotherapeutics-launches-with-103-million-to-develop-gene-therapies-for-kidney-disease
- Author: Amit Chowdhry
- Published: 2026-10-17T12:37:24+00:00
- Read time: 1 min
- Topics: estuary biotherapeutics, adpkd, gene therapy, kidney disease, polycystic kidney disease, pkd1, pkd2, series a, startups, business
## Estuary Biotherapeutics Launches
Estuary Biotherapeutics has launched with $103 million in committed financing to develop genetic medicines targeting serious kidney diseases.
## Funding Sources
The financing includes a $93 million Series A led by RA Capital Management with participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a…
## Lead Programs
The proceeds will support Estuary’s two lead programs, EST-201 and EST-101, through clinical proof of concept and further development of the company’s kidney-targeting platform.
## Program Targets
EST-201 targets patients with ADPKD caused by PKD2 mutations, while EST-101 targets patients with PKD1 mutations.
## Clinical Timeline
Estuary anticipates bringing EST-201 into the clinic in 2027 and EST-101 into the clinic in 2028.
## Key takeaway

Estuary Biotherapeutics received $103 million to create gene therapies targeting kidney disease.